Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Status:
Recruiting
Trial end date:
2029-10-31
Target enrollment:
Participant gender:
Summary
Patients will receive standard of care radiation therapy to the primary tumor of the head and
neck and involved nodal metastasis and draining nodal basin and either weekly cisplatin or
every 3-week cisplatin in locally advanced SCCHN. The relationship between cisplatin toxicity
and the level of reactive oxygen species generated by the drug in subjects with squamous cell
carcinoma of the head and neck treated on this trial.